Peptides
Explore 52 peptides with evidence ratings, safety profiles, and research-backed content.
52 peptides found
Semaglutide
Incretin/amylin analog
A well-studied GLP-1 receptor agonist with strong human evidence for weight management, type 2 diabetes, and selected cardiovascular and kidney outcomes.
Somatropin
GH/IGF axis peptide
Recombinant human growth hormone with strong evidence for approved pediatric, adult-deficiency, and wasting indications, but not broad anti-aging use.
Tirzepatide
Incretin/amylin analog
A dual GIP/GLP-1 agonist with strong human evidence for obesity, type 2 diabetes, weight maintenance, and obesity-related sleep apnea.
Cagrilintide
Incretin/amylin analog
A long-acting amylin analog studied for weight management and diabetes, with strongest public evidence in combination with semaglutide and no FDA-approved cagrilintide product.
hCG
Endocrine/reproductive hormone
A placental gonadotropin that activates LH/CG receptors, with strong supervised reproductive-medicine evidence for ovulation triggering and selected male hypogonadism contexts.
Oxytocin
Endocrine/reproductive hormone
A hypothalamic nonapeptide hormone used as an injectable obstetric medication, with strong supervised-care evidence and broader social-behavior research limits.
PT-141 (Bremelanotide)
Melanocortin pathway peptide
A cyclic melanocortin receptor agonist and Vyleesi ingredient, with strong evidence for labeled HSDD use and weaker broader libido data.
Retatrutide
Incretin/amylin analog
A once-weekly GIP/GLP-1/glucagon triple agonist in obesity trials, with strong phase 2 and topline phase 3 weight-loss data but no approved product yet.
SS-31
Mitochondrial peptide
A mitochondria-targeted tetrapeptide, also known as elamipretide, with strong Barth syndrome evidence and narrower support for general wellness claims.
Tesamorelin
GH/IGF axis peptide
A GHRH analog approved for HIV-associated lipodystrophy visceral-fat reduction, with strong human evidence and important glucose, IGF-1, and sports restrictions.
Cerebrolysin
Neuroactive peptide
A porcine brain-derived peptide and amino-acid mixture used in some countries for neurologic care, with human stroke and cognition evidence.
CJC-1295
GH/IGF axis peptide
A long-acting GHRH analog designed for sustained GH and IGF-1 signaling, with human biomarker evidence but limited outcome data.
CJC-1295 (no DAC)
GH/IGF axis peptide
A short-acting GHRH analog used for pulse-oriented GH-axis signaling, with indirect human support and limited direct no-DAC outcome evidence.
GHK-Cu
Matrikine/copper tripeptide
A well-characterized copper-binding tripeptide best known for topical skin remodeling, with relevant human data and weaker support for injectable or systemic use.
Glutathione
Redox/NAD metabolism compound
A naturally occurring tripeptide antioxidant central to redox balance and detoxification chemistry, with route-dependent supplementation and skin-pigmentation evidence.
Gonadorelin
Endocrine/reproductive hormone
A synthetic GnRH decapeptide used to assess or stimulate the reproductive axis, with strongest evidence in supervised fertility and pituitary-testing contexts.
Kisspeptin
Endocrine/reproductive hormone
A KISS1-derived neuropeptide that regulates GnRH signaling, with meaningful reproductive-endocrine evidence and protocol-specific fertility and hormone-axis applications.
Melanotan I
Melanocortin pathway peptide
A synthetic alpha-MSH analog and melanocortin agonist with strong disease-specific evidence for EPP photoprotection and more limited cosmetic-tanning data.
Nicotinamide Riboside (NR)
Redox/NAD metabolism compound
Nicotinamide riboside with a 300 mg daily oral trial preset and a separately identified 500 mg NR-chloride research vial protocol.
NMN
Redox/NAD metabolism compound
Oral nicotinamide mononucleotide with a human-trial 300 mg daily preset and a distinct identity from direct NAD+ and nicotinamide riboside.
Sermorelin
GH/IGF axis peptide
A GHRH(1-29) fragment that stimulates pituitary GH release, with historical approved-product evidence and limited adult wellness outcome support.
Thymosin Alpha-1
Immune signaling peptide
A thymic immune-modulating peptide, also called thymalfasin, with meaningful indication-specific clinical evidence in antiviral, immune, and vaccine-response contexts.
ARA-290
Endogenous fragment peptide
An EPO-derived tissue-protective peptide studied for small-fiber neuropathy and corneal nerve repair, with small human trials but no approved indication.
BPC-157
Endogenous fragment peptide
A gastric pentadecapeptide studied for gut, wound, vascular, and soft-tissue repair biology, with strong animal data but limited human outcomes.
GHR-2 (GHRP-2)
GH/IGF axis peptide
A pralmorelin-family growth-hormone secretagogue that stimulates GH and appetite signaling in human studies, with no FDA-approved U.S. indication and anti-doping restrictions.
GHRP-6
GH/IGF axis peptide
An early growth-hormone secretagogue known for GH release and appetite stimulation, with human endocrine studies but no FDA-approved U.S. indication.
Hexarelin
GH/IGF axis peptide
A synthetic GHRP-family secretagogue with human GH-release data and preclinical cardiac and metabolic rationale, but limited practical outcome evidence.
Ipamorelin
GH/IGF axis peptide
A selective ghrelin-receptor secretagogue with human GH pharmacology and postoperative GI trial data, but limited long-term wellness outcome evidence.
Palmitoyl Tripeptide-1
Matrikine/copper tripeptide
A topical matrikine-style cosmetic signal peptide used for collagen, elastin, and wrinkle-appearance support, with stronger finished-formula than isolated-peptide evidence.
Selank
Neuroactive peptide
A synthetic tuftsin analog studied for anxiety, stress resilience, immune modulation, and cognition-adjacent effects, with limited human evidence.
Semax
Neuroactive peptide
An intranasal ACTH(4-7) analog studied for cognition, focus, neuroprotection, and stroke recovery, with meaningful evidence limits outside regional clinical use.
TB-500
Endogenous fragment peptide
A thymosin beta-4 fragment discussed for wound, ocular, cardiac, and soft-tissue repair, with limited direct TB-500 human evidence.
VIP
Immune signaling peptide
A vasoactive intestinal peptide studied for pulmonary vascular, lung-injury, and inflammatory signaling contexts, with disease-specific evidence limits.
5-Amino-1MQ
Redox/NAD metabolism compound
A selective NNMT inhibitor studied for fat-mass and NAD+ metabolism, with mouse data and mechanistic rationale but no published human outcome trial.
AHK-Cu
Matrikine/copper tripeptide
A copper-binding hair-support tripeptide studied in follicle and dermal-cell models, with cosmetic relevance but no controlled human scalp-outcome trial.
DSIP
Neuroactive peptide
A delta sleep-inducing neuropeptide studied for sleep architecture, pain, and stress biology, with mixed human relevance and uncertain practical use.
Epithalon
Bioregulator peptide
A synthetic pineal bioregulator tetrapeptide studied for telomerase, circadian, and cellular-aging biology, with no proven anti-aging therapy role.
Humanin
Mitochondrial peptide
A mitochondria-derived peptide studied for cytoprotection, neuroprotection, metabolism, and aging biology, with credible research signals but no approved therapy.
IGF-1 LR3
GH/IGF axis peptide
A modified IGF-1 analog designed for longer IGF-axis signaling, with mostly preclinical muscle and recovery claims and notable safety uncertainty.
KPV
Melanocortin pathway peptide
An alpha-MSH-derived anti-inflammatory tripeptide studied in gut, skin, wound, and barrier models, with no established human therapeutic indication.
LL-37
Immune signaling peptide
A human cathelicidin antimicrobial peptide central to innate immunity and wound signaling, with topical trial activity and limited systemic-use support.
Melanotan II
Melanocortin pathway peptide
A cyclic melanocortin agonist best known for tanning and libido research, with human pigmentation signals and important regulator skin-safety warnings.
MOTS-c
Mitochondrial peptide
A mitochondria-derived peptide linked to metabolic stress signaling, AMPK biology, and exercise adaptation, with early human activity but limited outcome data.
NAD+
Redox/NAD metabolism compound
Direct NAD+—not NMN or NR—with exact compounded vial, nasal-spray, and metered topical presets and limited route-matched human evidence.
P21
Neuroactive peptide
A CNTF-derived neurotrophic research peptide studied in Alzheimer and neurogenesis models, with no established human cognitive-treatment evidence.
Pal-AHK
Matrikine/copper tripeptide
A palmitoylated AHK tripeptide used in cosmetic hair-support research, with formulation-dependent evidence and no controlled human scalp outcome data.
AOD-9604
GH/IGF axis peptide
A growth-hormone-fragment analog studied for fat metabolism, with mostly preclinical support, weak human weight-loss evidence, and regulator and sports concerns.
Dihexa
Neuroactive peptide
An angiotensin IV-derived nootropic research molecule studied mostly in preclinical neurotrophic models, with no established human cognitive-treatment evidence.
FOXO4-DRI
Cell-penetrating peptide
A D-retro-inverso senolytic research peptide designed to disrupt FOXO4-p53 signaling, with animal evidence and no established human protocol.
PEG-MGF
GH/IGF axis peptide
A PEGylated mechano-growth-factor fragment studied in muscle and repair biology, with preclinical rationale but no proven human muscle-growth outcome.
Pinealon
Bioregulator peptide
A short bioregulator tripeptide discussed for neuroprotection, cognition, and age-related biology, with low-confidence preclinical evidence and no established clinical use.
NA-Semax-Amidate
Neuroactive peptide
A modified Semax derivative designed for altered stability, with Semax-adjacent neurotrophin rationale but a major direct human-evidence gap.